Panel Discussion: Assessing the Increased Deal-Making Activity & Market Size Opportunity for Engagers in Immunology
Time: 4:00 pm
day: Conference Day One
Details:
- Where are we seeing investment and innovation in immune cell engagers in immunology?
- How are different risk-benefit profiles for engagers translating into deal-making in immunology (versus oncology)?
- What is the business case and trade-offs in deciding to pursue engagers in immunology with greater data requirements, and slower entry into patients and clinical trials?
- What is the potential for first-in-class engager approvals in the immunology space?
- What are the additional data package requirements that are attractive to pharma and that substantiate a pivot for engager assets from oncology into immunology?
